Phase I studies of nogitecan hydrochloride for Japanese

[1]  P. Houghton,et al.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors , 2004, Cancer Chemotherapy and Pharmacology.

[2]  S. Kudoh,et al.  pH‐dependent uptake of irinotecan and its active metabolite, SN‐38, by intestinal cells , 1999, International journal of cancer.

[3]  K. Eguchi,et al.  A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38 , 1995, Japanese journal of cancer research : Gann.

[4]  L. Grochow,et al.  Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. , 1994, Cancer research.

[5]  D. V. Von Hoff,et al.  Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. , 1992, Journal of the National Cancer Institute.

[6]  L. Grochow,et al.  Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. , 1992, Cancer research.

[7]  L. Grochow,et al.  Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. , 1991, Journal of medicinal chemistry.

[9]  M. Fukuoka,et al.  [A phase I study of weekly administration of CPT-11 in lung cancer]. , 1990, Gan to kagaku ryoho. Cancer & chemotherapy.

[10]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[11]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[12]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[13]  R J Reitemeier,et al.  Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. , 1972, Cancer chemotherapy reports.

[14]  J A Gottlieb,et al.  Treatment of malignant melanoma with camptothecin (NSC-100880). , 1972, Cancer chemotherapy reports.

[15]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .